Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

shankar besta

  • Home
  • Author: shankar besta

UK offshore wind build-out to depend on grid connections and market reforms, says GlobalData

The UK’s clean-power transition is moving into an infrastructure-intensive phase, with offshore wind, solar PV, and new nuclear capacity set to reshape the generation mix. Delivering this build-out will depend on faster grid connections, transmission reinforcement, and market reforms that preserve investor confidence while managing a more variable power system, according to GlobalData, a leading […]
Read more

Influencers view Meta’s Muse Wonder launch as major push to diversify beyond advertising into paid AI software, says GlobalData

Meta Platforms’ debut of its flagship frontier models, Muse Wonder and Muse Wonder Full, ignited extensive discussions among influencers on X during mid-October 2026. Many influencers characterized the release from Meta Superintelligence Labs as a decisive expansion beyond standard conversational chatbots into autonomous reasoning, domain-specific tasks, and complex coding workflows. Influencers viewed the launch, powered […]
Read more

Canada clean power push challenged by interprovincial grid limits, says GlobalData

Canada is entering a pivotal phase of power-sector expansion as federal tax credits, the phase-out of coal-fired generation, and accelerating industrial electrification drive substantial capital into wind, solar, and nuclear power. However, realizing the full potential of these clean additions will require overcoming persistent interprovincial transmission bottlenecks and modernizing regional grids, says GlobalData, a leading […]
Read more

Tirzepatide holds potential to outperform oral and injectable semaglutide for glycemic control and weight-loss in T2D, says GlobalData

Eli Lilly’s Mounjaro (tirzepatide) was more effective than both Novo Nordisk’s injectable Ozempic and oral Rybelsus (semaglutide) in helping adults with type 2 diabetes (T2D) achieve glycemic and weight-loss targets, according to real-world evidence presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026. The results highlight tirzepatide’s potential to address […]
Read more

Sweden’s north-south grid divide risks limiting value of new clean power capacity, says GlobalData

Sweden’s power sector is set for further renewable-led expansion, supported by industrial electrification, green hydrogen development, battery manufacturing, data centers, and continued wind investment. However, constrained transmission between generation-rich northern Sweden and demand centers in the south risks limiting the value of new capacity and widening regional electricity-price differences, says GlobalData, a leading intelligence and […]
Read more

Semaglutide dose escalation holds promise for cardiovascular edge over tirzepatide switch in T2D, says GlobalData

Adults with type 2 diabetes (T2D) who escalated their dose of Novo Nordisk’s Ozempic (semaglutide) experienced a lower observed risk of cardiovascular events than those who switched to Eli Lilly’s Mounjaro (tirzepatide), according to real-world cardiovascular outcomes data presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026. The results provide […]
Read more

ECARX’s Flyme acquisition to strengthen its position in software-defined vehicle market, says GlobalData

The automotive technology market is shifting toward software-defined vehicle architectures, where cockpit operating systems, centralized computing, over-the-air updates, and connected services increasingly determine vehicle differentiation and recurring revenue potential. The recent acquisition of Hubei Qiguang Technology by ECARX brings the intellectual property, R&D teams, and OEM contracts associated with Flyme Auto and Flyme OS fully […]
Read more

Oral semaglutide holds potential as alternative to injectable GLP-1s for weight loss, says GlobalData

New real-world data from the OCTANE study shows that patients who were overweight or had obesity continued to lose weight after switching from Novo’s injectable Wegovy (semaglutide) or Lilly’s Zepbound (tirzepatide) to the oral semaglutide. The findings, presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026, support oral semaglutide as […]
Read more

Orforglipron holds potential as differentiated oral option for weight and glycemic control in T2D, says GlobalData

Data presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 showed that Lilly’s Foundayo (orforglipron) was associated with greater reductions in both body weight and HbA1c than Novo’s Rybelsus (semaglutide) in adults with type 2 diabetes (T2D) who were overweight or had obesity. The results highlight orforglipron’s potential as a […]
Read more

APAC market cap rankings rewritten by AI, memory and China’s banks, reveals GlobalData

Asia-Pacific’s (APAC) corporate market capitalization rankings underwent a sharp reshuffle in the third quarter of 2026, with artificial intelligence (AI) infrastructure emerging as the dominant force behind the region’s biggest valuation gains. Taiwan Semiconductor Manufacturing Co (TSMC) retained the top spot, but the more striking shift was the surge in memory and semiconductor names, while […]
Read more

APAC automotive cross traffic alert systems market to record 2.1% CAGR over 2026-33, forecasts GlobalData

Cross traffic alert systems are radar-based systems that detects approaching vehicles from the sides when reversing and warns drivers about vehicles crossing behind them. From an industry perspective, their relevance in Asia-Pacific (APAC) is linked to the region’s dense urban environments, varied road conditions, and growing focus on practical vehicle safety features. Against this backdrop, […]
Read more

Fiber broadband to drive growth in New Zealand fixed communication market through 2031, forecasts GlobalData

New Zealand’s (NZ) fixed communication services market is poised for growth, driven by increasing demand for fixed broadband services and continued investments in fiber infrastructure. The market is forecast to rise from $1.6 billion in 2026 to $1.9 billion by 2031, as investments support the expansion of the country’s high-speed broadband capabilities, according to GlobalData, […]
Read more

Genentech’s approval in breast cancer among nine key value-driving biopharma catalysts in Q4 2026, reveals GlobalData

Several keenly anticipated approval decisions governing critical catalysts that can shape biopharma sentiment are expected in Q4 2024, alongside key clinical trial milestones that could influence the industry’s landscape. One of them is Genentech’s/Roche’s giredestrant, which faces two regulatory decisions in breast cancer; one is an  approval decision by November 30, for early-stage ER+/HER2- breast […]
Read more
1 2 3 … 139